心血管-肾脏-代谢2-3期患者早期联合使用GLP-1受体激动剂和SGLT2抑制剂 (GLP1-SGLT2-CKM)
早期添加GLP-1受体激动剂与SGLT2抑制剂治疗对心血管-肾脏-代谢2-3期肥胖和2型糖尿病成人患者死亡率和肾脏结局的关联:一项目标试验仿真研究
研究概览
详细说明
这是一项回顾性观察研究,采用目标试验模拟设计,使用来自TriNetX美国协作网络的常规电子健康记录数据。 该研究旨在比较患有肥胖、2型糖尿病和心血管-肾脏-代谢2-3期的成人中,开始使用GLP-1受体激动剂或SGLT2抑制剂后,采用不同早期治疗强化策略的36个月全因死亡率和主要心肾结局风险。 主要估计指标为36个月时的相对风险和绝对风险差异。
符合条件的参与者为年龄20岁及以上、患有肥胖和2型糖尿病,并符合心血管-肾脏-代谢2-3期标准的成人。 资格、暴露和结局均使用TriNetX电子健康记录数据进行操作化定义,包括ICD-10-CM诊断代码、体重指数至少27 kg/m²、糖化血红蛋白至少6.5%以及药物发放记录。 排除标准包括6个月内曾使用相关药物类别、12个月内患有重大心血管疾病或晚期肾脏疾病、6个月内发生重大心血管或肾脏事件,以及有任何非2型糖尿病、HIV、减重手术或实体器官移植史。
比较三种互斥的早期治疗强化策略:早期加用SGLT2抑制剂治疗、早期加用DPP-4抑制剂或磺脲类治疗,以及无早期加用治疗。 对于加用策略,索引日期为背景治疗开始后90天内加用治疗的起始日期。 对于无早期加用策略,索引日期为背景治疗开始后的90天界标点。
由于治疗分配非随机,使用多项倾向评分匹配处理非随机治疗选择,采用1:1最近邻无放回匹配,卡钳值为对数倾向评分标准差的0.2倍。 匹配后通过标准化均数差评估协变量平衡,任何残余不平衡在结局模型中进一步调整。 随访从索引日期开始,持续至感兴趣结局、死亡、最后记录就诊或2026年1月31日中的最早日期,并进行意向治疗和符合方案集分析。
主要结局为36个月内的全因死亡率。 次要结局包括主要不良心血管事件(定义为心脏骤停、心肌梗死或卒中)和主要不良肾脏事件(定义为终末期肾脏病、透析依赖或开始、肾衰竭或死亡)。 对早期加用治疗的成对比较估计36个月内的比较效应,并按心血管-肾脏-代谢分期、肥胖严重程度、基线肾功能和基线心血管合并症进行预设亚组分析。
研究类型
注册 (实际的)
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
纳入标准:
- 年龄20岁或以上的成年人。
- 肥胖,定义为体重指数(BMI)27 kg/m²或更高。
- 2型糖尿病,使用电子健康记录数据定义,包括诊断代码和/或糖化血红蛋白(HbA1c)6.5%或更高。
- 基线时符合心血管-肾脏-代谢(CKM)第2-3阶段标准。
- 已开始使用GLP-1受体激动剂或SGLT2抑制剂作为背景治疗。
- 根据背景治疗开始后90天内早期联合用药启动情况确定治疗策略分类,或在90天标志点无早期联合用药。
排除标准:
- 队列入组前6个月内曾使用GLP-1受体激动剂、SGLT2抑制剂、DPP-4抑制剂或磺脲类药物。
- 队列入组前12个月内患有重大心血管疾病或进行过血运重建。
- 队列入组前12个月内患有晚期肾脏疾病,包括终末期肾病、透析或估计肾小球滤过率低于15 mL/min/1.73 m²。
- 索引时间点前6个月内发生重大心血管或肾脏事件。
- 有任何非2型糖尿病史、HIV感染史、减重手术史或实体器官移植史。
- 缺失关键基线协变量。
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
GLP-1 RA Base Therapy
Adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3 who initiated a GLP-1 receptor agonist as base therapy after a 6-month washout from GLP-1 RA, SGLT2i, DPP-4i, and sulfonylureas.
Within this cohort, participants were classified by the first add-on treatment within 90 days into three mutually exclusive strategies: SGLT2i add-on, DPP-4i or sulfonylurea add-on, or no early add-on.
|
将胰高血糖素样肽-1受体激动剂作为基础疗法或附加疗法用于患有肥胖症、2型糖尿病以及心血管-肾脏-代谢2-3期的成人患者。
对于患有肥胖症、2型糖尿病以及心血管-肾脏-代谢疾病2-3期的成人患者,使用钠-葡萄糖协同转运蛋白-2抑制剂作为背景治疗或附加治疗。
|
|
SGLT2i Base Therapy
Adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3 who initiated an SGLT2 inhibitor as base therapy after a 6-month washout from GLP-1 RA, SGLT2i, DPP-4i, and sulfonylureas.
Within this cohort, participants were classified by the first add-on treatment within 90 days into three mutually exclusive strategies: GLP-1 RA add-on, DPP-4i or sulfonylurea add-on, or no early add-on.
|
将胰高血糖素样肽-1受体激动剂作为基础疗法或附加疗法用于患有肥胖症、2型糖尿病以及心血管-肾脏-代谢2-3期的成人患者。
对于患有肥胖症、2型糖尿病以及心血管-肾脏-代谢疾病2-3期的成人患者,使用钠-葡萄糖协同转运蛋白-2抑制剂作为背景治疗或附加治疗。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
All-cause Mortality (Comparison 1)
大体时间:From index through 36 months
|
All-cause mortality within 36 months in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with SGLT2i add-on versus GLP-1 RA with DPP-4 inhibitor or sulfonylurea add-on in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
All-cause Mortality (Comparison 2)
大体时间:From index through 36 months
|
All-cause mortality within 36 months in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with SGLT2i add-on versus GLP-1 RA without early add-on treatment in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
All-cause Mortality (Comparison 3)
大体时间:From index through 36 months
|
All-cause mortality within 36 months in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with GLP-1 RA add-on versus SGLT2i with DPP-4 inhibitor or sulfonylurea add-on in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
All-cause Mortality (Comparison 4)
大体时间:From index through 36 months
|
All-cause mortality within 36 months in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with GLP-1 RA add-on versus SGLT2i without early add-on treatment in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major Adverse Cardiovascular Events (MACE) (Comparison 1)
大体时间:From index through 36 months
|
Major adverse cardiovascular events within 36 months in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with SGLT2i add-on versus GLP-1 RA with DPP-4 inhibitor or sulfonylurea add-on in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
Major Adverse Cardiovascular Events (MACE) (Comparison 2)
大体时间:From index through 36 months
|
Major adverse cardiovascular events within 36 months in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with SGLT2i add-on versus GLP-1 RA without early add-on treatment in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
Major Adverse Cardiovascular Events (MACE) (Comparison 3)
大体时间:From index through 36 months
|
Major adverse cardiovascular events within 36 months in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with GLP-1 RA add-on versus SGLT2i with DPP-4 inhibitor or sulfonylurea add-on in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
Major Adverse Cardiovascular Events (MACE) (Comparison 4)
大体时间:From index through 36 months
|
Major adverse cardiovascular events within 36 months in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with GLP-1 RA add-on versus SGLT2i without early add-on treatment in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
Major Adverse Kidney Events (MAKE) (Comparison 1)
大体时间:From index through 36 months
|
Major adverse kidney events within 36 months in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with SGLT2i add-on versus GLP-1 RA with DPP-4 inhibitor or sulfonylurea add-on in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
Major Adverse Kidney Events (MAKE) (Comparison 2)
大体时间:From index through 36 months
|
Major adverse kidney events within 36 months in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with SGLT2i add-on versus GLP-1 RA without early add-on treatment in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
Major Adverse Kidney Events (MAKE) (Comparison 3)
大体时间:From index through 36 months
|
Major adverse kidney events within 36 months in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with GLP-1 RA add-on versus SGLT2i with DPP-4 inhibitor or sulfonylurea add-on in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
|
Major Adverse Kidney Events (MAKE) (Comparison 4)
大体时间:From index through 36 months
|
Major adverse kidney events within 36 months in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with GLP-1 RA add-on versus SGLT2i without early add-on treatment in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.
|
From index through 36 months
|
合作者和调查者
出版物和有用的链接
一般刊物
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
- Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.
- Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
- Asmar A, Cramon PK, Simonsen L, Asmar M, Sorensen CM, Madsbad S, Moro C, Hartmann B, Jensen BL, Holst JJ, Bulow J. Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2509-2519. doi: 10.1210/jc.2019-00004.
- Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Oct;61(10):2108-2117. doi: 10.1007/s00125-018-4670-7. Epub 2018 Aug 22.
- The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018. No abstract available.
- Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016 Nov;79:70-75. doi: 10.1016/j.jclinepi.2016.04.014. Epub 2016 May 27.
- Muller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschop MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30.
- Zhu R, Wang R, He J, Wang L, Chen H, Niu X, Sun Y, Guan Y, Gong Y, Zhang L, An P, Li K, Ren F, Xu W, Guo J. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health. JAMA Netw Open. 2024 Nov 4;7(11):e2445309. doi: 10.1001/jamanetworkopen.2024.45309.
- Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Curr Probl Cardiol. 2024 Feb;49(2):102344. doi: 10.1016/j.cpcardiol.2023.102344. Epub 2023 Dec 14.
- Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14.
- Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025 Apr;151(13):e771-e862. doi: 10.1161/CIR.0000000000001309. Epub 2025 Feb 27.
- Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.
- Upadhyay A. SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback. Kidney360. 2024 May 1;5(5):771-782. doi: 10.34067/KID.0000000000000425. Epub 2024 Mar 25.
- Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192. No abstract available.
- Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, Rajgopal Singh R, Elkind MSV; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184. Epub 2023 Oct 9.
- Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009 Dec;297(6):F1647-55. doi: 10.1152/ajprenal.00082.2009. Epub 2009 Sep 23.
- Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
- Hubbard RA, Gatsonis CA, Hogan JW, Hunter DJ, Normand ST, Troxel AB. "Target Trial Emulation" for Observational Studies - Potential and Pitfalls. N Engl J Med. 2024 Nov 28;391(21):1975-1977. doi: 10.1056/NEJMp2407586. Epub 2024 Nov 23. No abstract available.
- Cashin AG, Hansford HJ, Hernan MA, Swanson SA, Lee H, Jones MD, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Islam N, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sharp MK, Sterne JAC, Stuart EA, McAuley JH. Transparent Reporting of Observational Studies Emulating a Target Trial-The TARGET Statement. JAMA. 2025 Sep 23;334(12):1084-1093. doi: 10.1001/jama.2025.13350.
- Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025 Nov 3;135(21):e194751. doi: 10.1172/JCI194751. eCollection 2025 Nov 3.
- Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
- Dib BN, Swanson SA. Emulating a Target Trial Using Observational Data. JAMA Intern Med. 2025 Apr 1;185(4):459-460. doi: 10.1001/jamainternmed.2024.8129.
- Yadav K, Lewis RJ. Immortal Time Bias in Observational Studies. JAMA. 2021 Feb 16;325(7):686-687. doi: 10.1001/jama.2020.9151. No abstract available.
- Hernan MA, Dahabreh IJ, Dickerman BA, Swanson SA. The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful? Ann Intern Med. 2025 Mar;178(3):402-407. doi: 10.7326/ANNALS-24-01871. Epub 2025 Feb 18.
- Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Aug;24(8):631-650. doi: 10.1038/s41573-025-01183-8. Epub 2025 Apr 25.
- Huang YN, Liao WL, Huang JY, Lin YJ, Yang SF, Huang CC, Wang CH, Su PH. Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study. Diabetes Obes Metab. 2024 Nov;26(11):5222-5232. doi: 10.1111/dom.15869. Epub 2024 Aug 22.
- Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, Renoux C, Suissa S, Azoulay L. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024 Apr 25;385:e078242. doi: 10.1136/bmj-2023-078242.
- Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, Rajgopal Singh R, Elkind MSV, Rangaswami J; American Heart Association. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023 Nov 14;148(20):1636-1664. doi: 10.1161/CIR.0000000000001186. Epub 2023 Oct 9.
- American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S207-S238. doi: 10.2337/dc25-S010.
- Baker-Smith CM, Gauen AM, Petito LC, Khan SS, Allen NB. Prevalence of Cardiovascular-Kidney-Metabolic Stages in US Adolescents and Relationship to Social Determinants of Health. J Am Heart Assoc. 2025 May 20;14(10):e040269. doi: 10.1161/JAHA.124.040269. Epub 2025 May 15.
- American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S239-S251. doi: 10.2337/dc25-S011.
- Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020. JAMA. 2024 Jun 4;331(21):1858-1860. doi: 10.1001/jama.2024.6892.
- Tsai MK, Kao JT, Wong CS, Liao CT, Lo WC, Chien KL, Wen CP, Wu MS, Wu MY. Cardiovascular-kidney-metabolic syndrome and all-cause and cardiovascular mortality: A retrospective cohort study. PLoS Med. 2025 Jun 26;22(6):e1004629. doi: 10.1371/journal.pmed.1004629. eCollection 2025 Jun.
- Hirohama D, Fadista J, Ha E, Liu H, Abedini A, Levinsohn J, Vassalotti A, Zeng L, Li C, Mohandes S, Vitale S, Shungin D, Nguyen T, Niewczas MA, Olsson N, McAllister FE, Karihaloo A, Susztak K. The proteogenomic landscape of the human kidney and implications for cardio-kidney-metabolic health. Nat Med. 2025 Nov;31(11):3917-3929. doi: 10.1038/s41591-025-03872-8. Epub 2025 Aug 12.
- Verma S, Bhatta M, Davies M, Deanfield JE, Garvey WT, Jensen C, Kandler K, Kushner RF, Rubino DM, Kosiborod MN. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine. 2022 Nov 29;55:101737. doi: 10.1016/j.eclinm.2022.101737. eCollection 2023 Jan.
- Massy ZA, Drueke TB. Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations. Kidney Int Rep. 2024 Jun 6;9(9):2608-2618. doi: 10.1016/j.ekir.2024.05.033. eCollection 2024 Sep.
- Verma S, Sharma A, Zinman B, Ofstad AP, Fitchett D, Brueckmann M, Wanner C, Zwiener I, George JT, Inzucchi SE, Butler J, Mazer CD. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020 Jul;22(7):1141-1150. doi: 10.1111/dom.14015. Epub 2020 Mar 29.
- Bae JH. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes Metab J. 2025 May;49(3):386-402. doi: 10.4093/dmj.2025.0220. Epub 2025 May 1.
- Savignano FA, Crajoinas RO, Pacheco BPM, Campos LCG, Shimizu MHM, Seguro AC, Girardi ACC. Attenuated diuresis and natriuresis in response to glucagon-like peptide-1 in hypertensive rats are associated with lower expression of the glucagon-like peptide-1 receptor in the renal vasculature. Eur J Pharmacol. 2017 Sep 15;811:38-47. doi: 10.1016/j.ejphar.2017.05.054. Epub 2017 May 30.
- Lovshin J, Cherney D. GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering? Diabetes. 2015 Jul;64(7):2319-21. doi: 10.2337/db15-0366. No abstract available.
- Asmar A, Cramon PK, Asmar M, Simonsen L, Sorensen CM, Madsbad S, Hartmann B, Holst JJ, Hovind P, Jensen BL, Bulow J. The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor. J Clin Endocrinol Metab. 2021 Jan 1;106(1):e11-e19. doi: 10.1210/clinem/dgaa643.
- Yau K, Cherney DZI, van Raalte DH, Wever BE. Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect. Kidney Int. 2024 Jun;105(6):1168-1172. doi: 10.1016/j.kint.2024.03.019. No abstract available.
- Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. Hypertension. 2020 Apr;75(4):894-901. doi: 10.1161/HYPERTENSIONAHA.119.11684. Epub 2020 Mar 2.
- Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, Jones WS, Khan MS, Petrie MC, Udell JA, Friede T, Butler J. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024 Jul;12(7):447-461. doi: 10.1016/S2213-8587(24)00102-5. Epub 2024 May 17.
- Scheen AJ. GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs. 2024 Nov;84(11):1347-1364. doi: 10.1007/s40265-024-02090-9. Epub 2024 Sep 28.
- Pohlman N, Patel PN, Essien UR, Tang JJ, Joseph JJ. Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2105-2122. doi: 10.1210/clinem/dgaf295.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CS1-25149
- NSTC 113-2314-B-040-026-MY2 (其他赠款/资助编号:National Science and Technology Council, Taiwan)
- NSTC 114-2622-B-040-001 (其他赠款/资助编号:National Science and Technology Council, Taiwan)
- CSH-2025-C-012 (其他赠款/资助编号:Chung Shan Medical University Hospital)
- CSH-2025-C-023 (其他赠款/资助编号:Chung Shan Medical University Hospital)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.